In vitro susceptibility of Trichophyton rubrum isolates to griseofulvin and tioconazole. Induction and isolation of a resistant mutant to both antimycotic drugs: Mutant of Trichophyton rubrum resistant to griseofulvin and tioconazole

Mycopathologia

Volumn 135, Issue 3, 1996, Pages 141-143

  Fachin, Ana Lucia ^a   Maffei, Claudia Maria Leite ^a   Martinez Rossi, Nilce Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dermatophyte; Drug resistance; Fungi; Griseofulvin resistance; Tioconazole resistance; Trichophyton rubrum

Indexed keywords

ANTIFUNGAL AGENT; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; TIOCONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MUTATION; TRICHOPHYTON;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, MICROBIAL; GRISEOFULVIN; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MUTATION; TRICHOPHYTON;

FUNGI; TRICHOPHYTON; TRICHOPHYTON RUBRUM;

EID: 0030431872     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00632334     Document Type: Article

References (18)

1. Blank H, Roth FJ. The treatment of dermatomycoses with orally administered griseofulvin. Arch Dermatol 1959; 79: 259-266.
2. Blank H, Smith JG, Roth FJ, et al. Griseofulvin for the systemic treatment of dermatomycoses. Jama 1959; 171: 2168-2174.
3. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part I. J Am Acad Dermatol 1994; 30: 677-698.
4. Grisham LM, Wilson L, Bensch KG. Antimycotic action of griseofulvin does not involve disruption of microrubules. Nature 1973; 244: 294-296.
5. Gull K, Trinci APJ. Griseofulvin inhibits fungal mitosis. Nature 1973; 244: 292-294.
6. McNall EG. Biochemical studies on the metabolism of griseofulvin. Arch Dermatol 1960; 81: 657-661.
7. Brian PW. Griseofulvin. Trans Br Mycol Soc 1960; 43: 1-13.
8. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16-19.
9. Scholz R, Meinhof W. Susceptibility of Trichophyton rubrum to griseofulvin. Mycoses 1991; 34: 411-414.
10. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
11. Hay RJ, Clayton YM, Moore MK. Tioconazole nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-115.
12. Kelly SL, Kenna S, Bligh HFJ, Watson PF, Stansfield I, Ellis SW, Kelly DE. Lanosterol to ergosterol - enzymology, inhibition and genetics. In: Kuhn PJ, Trinci APS, Jung MJ, Goosey MW, Copping LG, eds. Biochemistry of walls and membranes in fungi. Germany: Springer-Verlag, 1990: 224-239.
13. McGinnis MR, ed. Laboratory handbook of Medical Mycology. Academic Press, New York, 1980.
14. Okeke CN, Gugnani HC. In vitro sensitivity of environmental isolates of pathogenic dermatiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative. Mycopathology 1987; 99: 175-181.
15. Endicott JA, Ling V. The biochemistry of glycoproteinmediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
16. Hirata D, Yano K, Miyakawa K, Miyakawa T. Saccharomyces cerevisiae YDR1, which encodes a member of the ATP-binding cassete (ABC) superfamily, is required for multidrug resistance. Curr Genet 1994; 26: 285-294.
17. Ben-Yaacov R, Knoller S, Caidwell G, Becker JM, Koltin Y. Candida albicans gene encoding resistance to benomyl and methotrexate is a multiresistance gene. Antimicrob Agents Chemother 1994; 38: 648-652.
18. Clark FS, Parkinson T, Hitchcock CA, Gow NAR. Correlation between Rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419-425.